JP2015522581A - サイトメガロウイルスタンパク質の複合体 - Google Patents

サイトメガロウイルスタンパク質の複合体 Download PDF

Info

Publication number
JP2015522581A
JP2015522581A JP2015519155A JP2015519155A JP2015522581A JP 2015522581 A JP2015522581 A JP 2015522581A JP 2015519155 A JP2015519155 A JP 2015519155A JP 2015519155 A JP2015519155 A JP 2015519155A JP 2015522581 A JP2015522581 A JP 2015522581A
Authority
JP
Japan
Prior art keywords
hcmv
complex
membrane protein
protein
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015519155A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015522581A5 (cg-RX-API-DMAC7.html
Inventor
アンドレア カルフィ，
アンドレア カルフィ，
インシア ウェン，
インシア ウェン，
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48783208&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2015522581(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ノバルティス アーゲー, ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2015522581A publication Critical patent/JP2015522581A/ja
Publication of JP2015522581A5 publication Critical patent/JP2015522581A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/03—Herpetoviridae, e.g. pseudorabies virus
    • C07K14/04—Varicella-zoster virus
    • C07K14/045—Cytomegalovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015519155A 2012-07-06 2013-06-29 サイトメガロウイルスタンパク質の複合体 Pending JP2015522581A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261668975P 2012-07-06 2012-07-06
US61/668,975 2012-07-06
US201361770257P 2013-02-27 2013-02-27
US61/770,257 2013-02-27
PCT/EP2013/063750 WO2014005959A1 (en) 2012-07-06 2013-06-29 Complexes of cytomegalovirus proteins

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2017149178A Division JP2017192399A (ja) 2012-07-06 2017-08-01 サイトメガロウイルスタンパク質の複合体
JP2017149179A Division JP2017192400A (ja) 2012-07-06 2017-08-01 サイトメガロウイルスタンパク質の複合体

Publications (2)

Publication Number Publication Date
JP2015522581A true JP2015522581A (ja) 2015-08-06
JP2015522581A5 JP2015522581A5 (cg-RX-API-DMAC7.html) 2016-07-14

Family

ID=48783208

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015519155A Pending JP2015522581A (ja) 2012-07-06 2013-06-29 サイトメガロウイルスタンパク質の複合体
JP2017149178A Pending JP2017192399A (ja) 2012-07-06 2017-08-01 サイトメガロウイルスタンパク質の複合体
JP2017149179A Pending JP2017192400A (ja) 2012-07-06 2017-08-01 サイトメガロウイルスタンパク質の複合体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017149178A Pending JP2017192399A (ja) 2012-07-06 2017-08-01 サイトメガロウイルスタンパク質の複合体
JP2017149179A Pending JP2017192400A (ja) 2012-07-06 2017-08-01 サイトメガロウイルスタンパク質の複合体

Country Status (17)

Country Link
US (4) US9683022B2 (cg-RX-API-DMAC7.html)
EP (1) EP2869843B1 (cg-RX-API-DMAC7.html)
JP (3) JP2015522581A (cg-RX-API-DMAC7.html)
KR (1) KR20150031322A (cg-RX-API-DMAC7.html)
CN (1) CN104853771A (cg-RX-API-DMAC7.html)
AU (1) AU2013286093B2 (cg-RX-API-DMAC7.html)
CA (1) CA2878344A1 (cg-RX-API-DMAC7.html)
ES (1) ES2753138T3 (cg-RX-API-DMAC7.html)
GB (1) GB2513768B (cg-RX-API-DMAC7.html)
HK (1) HK1210037A1 (cg-RX-API-DMAC7.html)
IL (1) IL236261A0 (cg-RX-API-DMAC7.html)
IN (1) IN2014KN02929A (cg-RX-API-DMAC7.html)
MX (2) MX355469B (cg-RX-API-DMAC7.html)
RU (1) RU2015103891A (cg-RX-API-DMAC7.html)
SG (1) SG11201408328VA (cg-RX-API-DMAC7.html)
WO (1) WO2014005959A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201409364B (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018531996A (ja) * 2015-10-22 2018-11-01 モデルナティーエックス， インコーポレイテッド ヒトサイトメガロウイルスワクチン
JP2020528911A (ja) * 2017-07-28 2020-10-01 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 異種ｒｅｐＲＮＡ免疫化のための方法および組成物
JP2020533354A (ja) * 2017-09-13 2020-11-19 サノフィ・パスツールＳａｎｏｆｉ Ｐａｓｔｅｕｒ ヒトサイトメガロウイルス免疫原性組成物

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2513768B (en) 2012-07-06 2015-04-15 Novartis Ag Complexes of cytomegalovirus proteins and nucleic acids encoding such proteins
CN104838000B (zh) 2012-07-27 2022-12-20 希望之城 一种递送ul128复合体和预防cmv感染的mva疫苗
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
ES2868427T3 (es) * 2013-12-03 2021-10-21 Hookipa Biotech Ag Vacunas contra el CMV
AU2015251221A1 (en) * 2014-04-23 2016-10-27 CARIPLO, Fondazione Human cytomegalovirus vaccine compositions and method of producing the same
WO2015165480A1 (en) * 2014-04-30 2015-11-05 Institute For Research In Biomedicine Human cytomegalovirus vaccine compositions and method of producing the same
PE20170301A1 (es) * 2014-05-08 2017-03-30 Pfizer Medios y metodos para el tratamiento cmv
EP3015475A1 (en) 2014-10-31 2016-05-04 Novartis AG Mammalian cells expressing cytomegalovirus antigens
EP3048114A1 (en) * 2015-01-22 2016-07-27 Novartis AG Cytomegalovirus antigens and uses thereof
EP3047856A1 (en) * 2015-01-23 2016-07-27 Novartis AG Cmv antigens and uses thereof
EP3347045A4 (en) 2015-09-10 2019-08-28 City of Hope MVA-GH / GL-PC VACCINATED ANTIBODIES FOR NEUTRALIZING THE INFECTIOSITY OF HUMAN CYTOMEGALOVIRUS AND METHOD THEREFOR
CN113181106A (zh) 2016-01-11 2021-07-30 沃达瑞公司 微针组合物及其使用方法
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
EP3528821A4 (en) 2016-10-21 2020-07-01 ModernaTX, Inc. HUMAN CYTOMEGALOVIRUS VACCINE
JP2020515522A (ja) * 2017-01-27 2020-05-28 ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド 免疫応答を誘導するヘルペスウイルスエンベロープタンパク質の組み合わせのワクチン組成物
WO2018187325A1 (en) 2017-04-04 2018-10-11 University Of Washington Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use
US20230248820A1 (en) 2017-04-19 2023-08-10 Glaxosmithkline Biologicals, S.A. Modified cytomegalovirus proteins and stabilized complexes
EP3658581A1 (en) * 2017-07-24 2020-06-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies and peptides to treat hcmv related diseases
EP3758747A1 (en) * 2018-02-28 2021-01-06 University of Washington Self-asssembling nanostructure vaccines
IL278418B2 (en) 2018-05-04 2024-01-01 Spybiotech Ltd Vaccine composition
JP7584405B2 (ja) * 2018-10-17 2024-11-15 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 改変されたサイトメガロウイルスタンパク質及び安定化された複合体
AU2019397719B2 (en) 2018-12-10 2023-11-09 Km Biologics Co., Ltd. Vaccine for preventing or treating congenital infection with cytomegalovirus
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
EP4004018A1 (en) 2019-07-24 2022-06-01 GlaxoSmithKline Biologicals SA Modified human cytomegalovirus proteins
KR102837045B1 (ko) * 2020-06-09 2025-07-23 케이엠 바이올로직스 가부시키가이샤 사이토메갈로바이러스의 gB와 펜타머의 융합 단백질 및 당해 융합 단백질을 포함하는 백신
TWI810589B (zh) 2020-06-21 2023-08-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
AU2021367917A1 (en) 2020-10-28 2023-06-22 Sanofi Pasteur Liposomes containing tlr4 agonist, preparation and uses thereof
PE20240083A1 (es) * 2021-02-24 2024-01-16 Pfizer Nuevas regiones modulables farmacologicamente en el polipeptido de la glicoproteina b del citomegalovirus humano y metodos de uso de las mismas
US20250101067A1 (en) 2022-01-28 2025-03-27 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004076645A2 (en) * 2003-02-27 2004-09-10 University Of Massachusetts Compositions and methods for cytomegalovirus treatment
JP2009539845A (ja) * 2006-06-07 2009-11-19 トラスティーズ オブ プリンストン ユニバーシティ ワクチン中に薬剤標的として用いるサイトメガロウイルス表面タンパク質複合体
WO2012051211A2 (en) * 2010-10-11 2012-04-19 Novartis Ag Antigen delivery platforms

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1201757A3 (en) 1988-12-22 2002-09-11 Genentech, Inc. Method for preparing water soluble polypeptides
US5364780A (en) 1989-03-17 1994-11-15 E. I. Du Pont De Nemours And Company External regulation of gene expression by inducible promoters
WO1992002628A1 (en) 1990-08-02 1992-02-20 Chiron Corporation Expression of human cmv glycoprotein-h using the baculovirus-insect cell expression system
US5474914A (en) * 1992-07-29 1995-12-12 Chiron Corporation Method of producing secreted CMV glycoprotein H
US5362865A (en) 1993-09-02 1994-11-08 Monsanto Company Enhanced expression in plants using non-translated leader sequences
US5693506A (en) 1993-11-16 1997-12-02 The Regents Of The University Of California Process for protein production in plants
US5815900A (en) 1995-03-06 1998-10-06 Matsushita Electric Industrial Co., Ltd. Method of manufacturing a surface acoustic wave module
US7947274B2 (en) * 2007-01-04 2011-05-24 Humabs, LLC. Human cytomegalovirus neutralising antibodies and use thereof
US9439960B2 (en) 2007-10-10 2016-09-13 The Trustees Of Princeton University Cytomegalovirus vaccines and methods of production
EA026401B1 (ru) 2009-09-02 2017-04-28 Новартис Аг Иммуногенные композиции, содержащие модуляторы активности tlr
US9089537B2 (en) * 2010-02-26 2015-07-28 The Trustees Of The University Of Pennslyvania Subunit vaccines for herpes viruses and methods of use
CA2804591C (en) 2010-07-06 2019-01-22 Novartis Ag Cationic oil-in-water emulsions
PL2590626T3 (pl) 2010-07-06 2016-04-29 Glaxosmithkline Biologicals Sa Liposomy z lipidami o korzystnej wartości pka do dostarczania rna
WO2012015211A2 (ko) 2010-07-30 2012-02-02 주식회사종근당 사이클로스포린 에이 함유 점안제 조성물
EP2614072A4 (en) * 2010-09-09 2014-03-19 Univ Virginia Commonwealth VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS
MX352974B (es) * 2011-01-31 2017-12-15 Univ Pennsylvania Moleculas de acido nucleico que codifican novedosos antigenos de herpes, vacunas que las comprenden y metodos para su uso.
US11058762B2 (en) 2011-07-06 2021-07-13 Glaxosmithkline Biologicals Sa Immunogenic compositions and uses thereof
MX350258B (es) * 2011-07-06 2017-08-31 Novartis Ag Emulsiones cationicas de aceite en agua.
PT2750707T (pt) * 2011-08-31 2019-01-23 Glaxosmithkline Biologicals Sa Lipossomas peguilados para distribuição de arn que codifica imunogénio
GB2513768B (en) 2012-07-06 2015-04-15 Novartis Ag Complexes of cytomegalovirus proteins and nucleic acids encoding such proteins
EP3015475A1 (en) 2014-10-31 2016-05-04 Novartis AG Mammalian cells expressing cytomegalovirus antigens

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004076645A2 (en) * 2003-02-27 2004-09-10 University Of Massachusetts Compositions and methods for cytomegalovirus treatment
JP2009539845A (ja) * 2006-06-07 2009-11-19 トラスティーズ オブ プリンストン ユニバーシティ ワクチン中に薬剤標的として用いるサイトメガロウイルス表面タンパク質複合体
WO2012051211A2 (en) * 2010-10-11 2012-04-19 Novartis Ag Antigen delivery platforms

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF CLINICAL VIROLOGY, vol. 25, JPN6017014714, 2002, pages 87 - 95, ISSN: 0003714151 *
JOURNAL OF VIROLOGY, vol. 82, no. 1, JPN6017014712, 2008, pages 60 - 70, ISSN: 0003714150 *
PROC. NATL. ACAD. SCI., USA, vol. 105, no. 37, JPN6017014715, 2008, pages 14118 - 14123, ISSN: 0003714152 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018531996A (ja) * 2015-10-22 2018-11-01 モデルナティーエックス， インコーポレイテッド ヒトサイトメガロウイルスワクチン
JP2021175745A (ja) * 2015-10-22 2021-11-04 モデルナティーエックス， インコーポレイテッド ヒトサイトメガロウイルスワクチン
JP7278677B2 (ja) 2015-10-22 2023-05-22 モデルナティエックス インコーポレイテッド ヒトサイトメガロウイルスワクチン
JP2023075344A (ja) * 2015-10-22 2023-05-30 モデルナティエックス インコーポレイテッド ヒトサイトメガロウイルスワクチン
JP2025010575A (ja) * 2015-10-22 2025-01-22 モデルナティエックス インコーポレイテッド ヒトサイトメガロウイルスワクチン
JP2020528911A (ja) * 2017-07-28 2020-10-01 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 異種ｒｅｐＲＮＡ免疫化のための方法および組成物
US11964007B2 (en) 2017-07-28 2024-04-23 Janssen Vaccines & Prevention B.V. Methods and compositions for heterologous repRNA immunizations
JP2020533354A (ja) * 2017-09-13 2020-11-19 サノフィ・パスツールＳａｎｏｆｉ Ｐａｓｔｅｕｒ ヒトサイトメガロウイルス免疫原性組成物
JP7770767B2 (ja) 2017-09-13 2025-11-17 サノフィ・パスツール ヒトサイトメガロウイルス免疫原性組成物

Also Published As

Publication number Publication date
MX2014015496A (es) 2015-03-06
JP2017192400A (ja) 2017-10-26
WO2014005959A1 (en) 2014-01-09
ZA201409364B (en) 2017-08-30
GB201413863D0 (en) 2014-09-17
RU2015103891A (ru) 2016-08-27
US9683022B2 (en) 2017-06-20
JP2017192399A (ja) 2017-10-26
SG11201408328VA (en) 2015-02-27
IN2014KN02929A (cg-RX-API-DMAC7.html) 2015-05-08
US20170320916A1 (en) 2017-11-09
MX378747B (es) 2025-03-10
GB2513768A (en) 2014-11-05
CA2878344A1 (en) 2014-01-09
US20190211064A1 (en) 2019-07-11
EP2869843A1 (en) 2015-05-13
HK1210037A1 (en) 2016-04-15
ES2753138T3 (es) 2020-04-07
CN104853771A (zh) 2015-08-19
EP2869843B1 (en) 2019-08-07
AU2013286093B2 (en) 2018-01-04
US20160159864A1 (en) 2016-06-09
IL236261A0 (en) 2015-02-26
US10287322B2 (en) 2019-05-14
AU2013286093A1 (en) 2015-02-12
MX355469B (es) 2018-04-19
US20220106364A1 (en) 2022-04-07
GB2513768B (en) 2015-04-15
KR20150031322A (ko) 2015-03-23

Similar Documents

Publication Publication Date Title
US20220106364A1 (en) Complexes of cytomegalovirus proteins
KR102242990B1 (ko) 헤테로다이머 면역글로불린 구조체 및 이의 제조 방법
CN114957475B (zh) 抗b7-h3的单克隆抗体及其在细胞治疗中的应用
CN108373504B (zh) Cd24特异性抗体和抗cd24-car-t细胞
US20190307879A1 (en) Adenovirus-vectored multivalent vaccine
CN114729031B (zh) 抗溶瘤病毒抗原抗体及其使用方法
Zhao et al. Immunization with Fc-based recombinant Epstein–Barr virus gp350 elicits potent neutralizing humoral immune response in a BALB/c mice model
CN114805582B (zh) 抗Trop2纳米抗体及其用途
EP3226892A1 (en) Dna antibody constructs and method of using same
CN109321530B (zh) 一种安全型嵌合抗原受体t细胞及其用途
KR20230042222A (ko) 중증 급성 호흡기 증후군 코로나바이러스 2(sars-cov-2) 폴리펩티드 및 백신 목적을 위한 이의 용도
US20250255960A1 (en) Anti-cd70 nanoantibody and use thereof
CN118580323A (zh) Rsv融合前f蛋白的突变体及其制备和应用
CN118406159B (zh) RSV pre-F截短体及其生产方法和应用
JP6538151B2 (ja) 抗ｃ型肝炎抗体及びその抗原結合断片
CN118812719A (zh) 特异性结合HBV pre-S1抗原和CD3抗原的多特异性抗体及其应用
US20240287166A1 (en) Dna antibody constructs for use against plasmodium parasites
CN115772544B (zh) 抗vegf-a和ang-2的aav载体
CN117264055A (zh) 一种特异性结合人cd318的vhh抗体或其抗原结合片段及其制备方法和应用
CN118496368B (zh) Trop2抗体或其抗原结合片段及其应用
EP4628095A1 (en) Fusion protein and granulated antigen comprising same
CN119708170B (zh) RSV pre-F突变体及其制备方法和应用
HK40068895B (zh) 一种抗tigit免疫抑制剂及应用
HK40004712A (en) Heterodimeric immunoglobulin constructs and preparation methods thereof
HK40011240B (zh) 靶向埃博拉病毒糖蛋白内部融合环的广泛中和抗体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160525

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160525

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170501

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170801

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180308

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180709